Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 5Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 105Carcinoma, Hepatocellular 34Gastrointestinal Stromal Tumors 17Colonic Neoplasms 14Rectal Neoplasms 12Neoplasm Metastasis 12Liver Neoplasms 8Stomach Neoplasms 5Cholangiocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Sarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Colorectal Cancer Metastatic 3Carcinoma, Renal Cell 3Advanced Colorectal Cancer 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Lung Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Fatigue 2Esophageal Squamous Cell Carcinoma 2Colorectal Cancer Liver Metastases 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2

Interventions

X-Rays 4Phantoms, Imaging 4Cyclophosphamide 4fludarabine 3Specimen Handling 3Melphalan 3Magnetic Resonance Spectroscopy 3ulixertinib 2tipifarnib 2tazemetostat 2talazoparib 2selpercatinib 2palbociclib 2ivosidenib 2Vemurafenib 2Temozolomide 2Sirolimus 2Nuclear Medicine Department, Hospital 2Nivolumab 2LY3023414 2Granulocyte Colony-Stimulating Factor 2Busulfan 2regorafenib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1omburtamab I-131 1olaparib 1larotrectinib 1irinotecan sucrosofate 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × regorafenib × Gastrointestinal × Clear all
NCT02085148 2024-04-22

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Bayer

Phase 1 Completed
62 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡